(Q51184997)

1 April 2018

review article

1 reference

title

[Role of voriconazole in critically ill patients with invasive mycoses]. (English)

1 reference

1 April 2018

1 reference

1 reference

Francisco Alvarez Lerma

series ordinal

1

1 reference

1 April 2018

publication date

1 September 2007

1 reference

1 April 2018

Revista iberoamericana de micologia

published in

1 reference

1 April 2018

volume

24

1 reference

1 April 2018

issue

3

1 reference

1 April 2018

page(s)

209-212

1 reference

1 April 2018

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Combination antifungal therapy for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Voriconazole salvage treatment of invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC)

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970044-X

7 January 2021

10.1016/S1130-1406(07)70044-X

Identifiers

DOI

1 reference

1 April 2018

release_s6zqkzjipncnppgk2vd3fozq7u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s6zqkzjipncnppgk2vd3fozq7u

24 November 2022

mapped directly with Wikidata item

1 reference

1 April 2018